|
1
|
Anastassopoulou C, Russo L, Tsakris A and
Siettos C: Data-based analysis, modelling and forecasting of the
COVID-19 outbreak. PLoS One. 15(e0230405)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Coronaviridae Study Group of the
International Committee on Taxonomy of Viruses. The species Severe
acute respiratory syndrome-related coronavirus: Classifying
2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 5:536–544. 2020.
View Article : Google Scholar
|
|
3
|
Almeida JD and Tyrrell DAJ: The morphology
of three previously uncharacterized human respiratory viruses that
grow in organ culture. J Gen Virol. 1:175–178. 1967.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Docea AO, Tsatsakis A, Albulescu D,
Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou
M, Drakoulis N, et al: A new threat from an old enemy: Re emergence
of coronavirus (Review). Int J Mol Med. 45:1631–1643.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP
and Jin DY: Zoonotic origins of human coronaviruses. Int J Biol
Sci. 16:1686–1697. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ksiazek TG, Erdman D, Goldsmith CS, Zaki
SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, et al:
SARS Working Group: A novel coronavirus associated with severe
acute respiratory syndrome. N Engl J Med. 348:1953–1966.
2003.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fehr AR, Channappanavar R and Perlman S:
Middle East respiratory syndrome (MERS): Emergence of a pathogenic
human Coronavirus. Annu Rev Med. 68:387–399. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H,
Wang W, Song H, Huang B, Zhu N, et al: Genomic characterisation and
epidemiology of 2019 novel coronavirus: Implications for virus
origins and receptor binding. Lancet. 395:565–574. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gates B: Responding to Covid-19 - A
Once-in-a-Century Pandemic? N Engl J Med. 382:1677–1679.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gates B: Innovation for Pandemics. N Engl
J Med. 378:2057–2060. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wu G, Zhao T, Kang D, Zhang J, Song Y,
Namasivayam V, Kongsted J, Pannecouque C, De Clercq E, Poongavanam
V, et al: Overview of recent strategic advances in medicinal
chemistry. J Med Chem. 62:9375–9414. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Touret F and de Lamballerie X: Of
chloroquine and COVID-19. Antiviral Res. 177(104762)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cortegiani A, Ingoglia G, Ippolito M,
Giarratano A and Einav S: A systematic review on the efficacy and
safety of chloroquine for the treatment of COVID-19. J Crit Care.
57:279–283. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Colson P, Rolain JM, Lagier JC, Brouqui P
and Raoult D: Chloroquine and hydroxychloroquine as available
weapons to fight COVID-19. Int J Antimicrob Agents.
55(105932)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ben-Zvi I, Kivity S, Langevitz P and
Shoenfeld Y: Hydroxychloroquine: From malaria to autoimmunity. Clin
Rev Allergy Immunol. 42:145–153. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Witiak DT, Grattan DA, Heaslip RJ and
Rahwan RG: Synthesis and preliminary pharmacological evaluation of
asymmetric chloroquine analogues. J Med Chem. 24:712–717.
1981.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chloroquine- an overview | ScienceDirect
Topics. Sci Direct.
|
|
18
|
Circu M, Cardelli J, Barr MP, O'Byrne K,
Mills G and El-Osta H: Modulating lysosomal function through
lysosome membrane permeabilization or autophagy suppression
restores sensitivity to cisplatin in refractory non-small-cell lung
cancer cells. PLoS One. 12(e0184922)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Schrezenmeier E and Dörner T: Mechanisms
of action of hydroxychloroquine and chloroquine: Implications for
rheumatology. Nat Rev Rheumatol. 16:155–166. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
van den Borne BEEM, Dijkmans BAC, de Rooij
HH, le Cessie S and Verweij CL: Chloroquine and hydroxychloroquine
equally affect tumor necrosis factor-α, interleukin 6, and
interferon-γ production by peripheral blood mononuclear cells. J
Rheumatol. 24:55–60. 1997.PubMed/NCBI
|
|
21
|
Gordon DE, Jang GM, Bouhaddou M, Xu J,
Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et
al: A SARS-CoV-2 protein interaction map reveals targets for drug
repurposing. Nature. Apr 30. 2020.(Epub ahead of print).PubMed/NCBI View Article : Google Scholar
|
|
22
|
Encinar JA and Menendez JA: Potential
drugs targeting early innate immune evasion of SARS-coronavirus 2
via 2'-O-methylation of viral RNA. Viruses. 12(E525)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Keyaerts E, Vijgen L, Maes P, Neyts J and
Van-Ranst M: In vitro inhibition of severe acute respiratory
syndrome coronavirus by chloroquine. Biochem Biophys Res Commun.
323:264–268. 2004.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu
M, Shi Z, Hu Z, Zhong W and Xiao G: Remdesivir and chloroquine
effectively inhibit the recently emerged novel coronavirus
(2019-nCoV) in vitro. Cell Res. 30:269–271. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H,
Li Y, Hu Z, Zhong W and Wang M: Hydroxychloroquine, a less toxic
derivative of chloroquine, is effective in inhibiting SARS-CoV-2
infection in vitro. Cell Discov. 6(16)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hache Guillaume RJMGP, DJBPRDHS:
Hydroxychloroquine-Azithromycin and COVID-19 - IHU, 2020.
|
|
27
|
Rosenberg ES, Dufort EM, Udo T,
Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse
A, DeHovitz J, et al: Association of treatment with
hydroxychloroquine or azithromycin with in-Hospital Mortality in
patients with COVID-19 in New York State. JAMA. May 11.
2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print). View Article : Google Scholar
|
|
28
|
Doudier B and Courjon J:
Hydroxychloroquine and azithromycin as a treatment of COVID-19.
2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gao J, Tian Z and Yang X: Breakthrough:
Chloroquine phosphate has shown apparent efficacy in treatment of
COVID-19 associated pneumonia in clinical studies. Biosci Trends.
14:72–73. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhao M: Cytokine storm and
immunomodulatory therapy in COVID-19: Role of chloroquine and
anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents.
55(105982)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Efficacy and safety of hydroxychloroquine
for treatment of COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov.
|
|
32
|
Comparison of lopinavir/ritonavir or
hydroxychloroquine in patients with mild coronavirus disease
(COVID-19). uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04307693.
Accessed March 13, 2020.
|
|
33
|
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu
P, Liu X, Zhao L, Dong E, Song C, et al: In vitro antiviral
activity and projection of optimized dosing design of
hydroxychloroquine for the treatment of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. Mar 9.
2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print). View Article : Google Scholar
|
|
34
|
The PATCH Trial (prevention and treatment
of COVID-19 with hydroxychloroquine). uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04329923.
Accessed April 1, 2020.
|
|
35
|
Karalis V, Ismailos G and Karatza E:
Chloroquine dosage regimens in patients with COVID-19: safety risks
and optimization using simulations. Saf Sci.
129(104842)2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lane JC, Weaver J, Kostka K, Duarte-Salles
T, Abrahao MT, Alghoul H, Alser O, Alshammari TM, Biedermann P,
Burn E, et al: Safety of hydroxychloroquine, alone and in
combination with azithromycin, in light of rapid wide-spread use
for COVID-19: a multinational, network cohort and self-controlled
case series study. medRxiv. May 31. 2020. View Article : Google Scholar : (Epub ahead of
print). View Article : Google Scholar
|
|
37
|
Al-Bari MA: Chloroquine analogues in drug
discovery: New directions of uses, mechanisms of actions and toxic
manifestations from malaria to multifarious diseases. J Antimicrob
Chemother. 70:1608–1621. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Mehra MR, Desai SS, Ruschitzka F and Patel
AN: Articles Hydroxychloroquine or chloroquine with or without a
macrolide for treatment of COVID-19: A multinational registry
analysis. Lancet. 6736:1–10. 2020. View Article : Google Scholar
|
|
39
|
Karalis V, Ismailos G and Karatza E:
Chloroquine dosage regimens in patients with COVID-19: Safety risks
and optimization using simulations. Saf Sci.
129(104842)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Driggin E, Madhavan MV, Bikdeli B, Chuich
T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar
DA, Haythe J, et al: Cardiovascular considerations for patients,
health care workers, and health systems during the COVID-19
pandemic. J Am Coll Cardiol. 75:2352–2371. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Deftereos SG, Siasos G, Giannopoulos G,
Vrachatis DA, Angelidis C, Giotaki SG, Gargalianos P, Giamarellou
H, Gogos C, Daikos G, et al: The Greek study in the effects of
colchicine in COvid-19 complications prevention (GRECCO-19 study):
Rationale and study design. Hellenic J Cardiol. Apr 3.
2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print). View Article : Google Scholar
|
|
42
|
Colchicine Coronavirus SARS-CoV2 Trial
(COLCORONA). uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04322682.
Accessed March 26, 2020.
|
|
43
|
Walls AC, Park YJ, Tortorici MA, Wall A,
McGuire AT and Veesler D: Structure, function, and antigenicity of
the SARS-CoV-2 spike glycoprotein. Cell.
181(281-292.e6)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Morse JS, Lalonde T, Xu S and Liu WR:
Learning from the past: Possible urgent prevention and treatment
options for severe acute respiratory infections caused by
2019-nCoV. ChemBioChem. 21:730–738. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Li F: Receptor recognition and
cross-species infections of SARS coronavirus. Antiviral Res.
100:246–254. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Ocaranza MP, Michea L, Chiong M, Lagos CF,
Lavandero S and Jalil JE: Recent insights and therapeutic
perspectives of angiotensin-(1-9) in the cardiovascular system.
Clin Sci (Lond). 127:549–557. 2014.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Li SR, Tang ZJ, Li ZH and Liu X: Searching
therapeutic strategy of new coronavirus pneumonia from
angiotensin-converting enzyme 2: the target of COVID-19 and
SARS-CoV. Eur J Clin Microbiol Infect Dis. 39:1021–1026.
2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Yan T, Xiao R and Lin G:
Angiotensin-converting enzyme 2 in severe acute respiratory
syndrome coronavirus and SARS-CoV-2: A double-edged sword? FASEB J.
34:6017–6026. 2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Imai Y, Kuba K and Penninger JM: The
discovery of angiotensin-converting enzyme 2 and its role in acute
lung injury in mice. Exp Physiol. 93:543–548. 2008.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Rothlin RP, Vetulli HM, Duarte M and
Pelorosso FG: Telmisartan as tentative angiotensin receptor blocker
therapeutic for COVID-19. Drug Dev Res. May 1. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print). View Article : Google Scholar
|
|
51
|
Zhang H, Penninger JM, Li Y, Zhong N and
Slutsky AS: Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2
receptor: Molecular mechanisms and potential therapeutic target.
Intensive Care Med. 46:586–590. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Thanh Le T, Andreadakis Z, Kumar A, Gómez
Román R, Tollefsen S, Saville M and Mayhew S: The COVID-19 vaccine
development landscape. Nat Rev Drug Discov. 19:305–306.
2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell.
181(271-280.e8)2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Iwata-Yoshikawa N, Okamura T, Shimizu Y,
Hasegawa H, Takeda M and Nagata N: TMPRSS2 contributes to virus
spread and immunopathology in the airways of murine models after
coronavirus infection. J Virol. 93(93)2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Verdecchia P, Cavallini C, Spanevello A
and Angeli F: The pivotal link between ACE2 deficiency and
SARS-CoV-2 infection. Eur J Intern Med. 76:14–20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Saavedra JM: Angiotensin receptor blockers
and COVID-19. Pharmacol Res. 156(104832)2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Fang L, Karakiulakis G and Roth M: Are
patients with hypertension and diabetes mellitus at increased risk
for COVID-19 infection? Lancet Respir Med. 8(e21)2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Diaz JH: Hypothesis:
angiotensin-converting enzyme inhibitors and angiotensin receptor
blockers may increase the risk of severe COVID-19 Running Title:
Angiotensin Receptor and COVID-19. J Travel Med.
27(taaa041)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Gurwitz D: Angiotensin receptor blockers
as tentative SARS-CoV-2 therapeutics. Drug Dev Res.
1(4)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie
J, Liu YM, Zhao YC, Huang X, Lin L, et al: Association of inpatient
use of angiotensin converting enzyme inhibitors and angiotensin II
receptor blockers with mortality among patients with hypertension
hospitalized with COVID-19. Circ Res. 126:1671–1681.
2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Castiglione V, Chiriacò M, Emdin M, Taddei
S and Vergaro G: Statin therapy in COVID-19 infection. Eur Heart J
Cardiovasc Pharmacother. Apr 29. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print). View Article : Google Scholar
|
|
62
|
Pertzov B, Eliakim-Raz N, Atamna H,
Trestioreanu AZ, Yahav D and Leibovici L: Hydroxymethylglutaryl-CoA
reductase inhibitors (statins) for the treatment of sepsis in
adults - A systematic review and meta-analysis. Clin Microbiol
Infect. 25:280–289. 2019.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Fedson DS, Opal SM and Rordam OM: Hiding
in plain sight: An approach to treating patients with severe
covid-19 infection. mBio. 11(e00398-20)2020.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Journal EH, Pharmacotherapy C, East M: OUP
accepted manuscript. Eur Hear J Cardiovasc Pharmacother 2020.
|
|
65
|
Li G and De Clercq E: Therapeutic options
for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov.
19:149–150. 2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Warren TK, Jordan R, Lo MK, Ray AS,
Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, et
al: Therapeutic efficacy of the small molecule GS-5734 against
Ebola virus in rhesus monkeys. Nature. 531:381–385. 2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Cho A, Saunders OL, Butler T, Zhang L, Xu
J, Vela JE, Feng JY, Ray AS and Kim CU: Synthesis and antiviral
activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine
C-nucleosides. Bioorg Med Chem Lett. 22:2705–2707. 2012.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Stambaský J, Hocek M and Kocovský P:
C-nucleosides: Synthetic strategies and biological applications.
Chem Rev. 109:6729–6764. 2009.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Eastman RT, Roth JS, Brimacombe KR,
Simeonov A, Shen M, Patnaik S and Hall MD: Remdesivir: A review of
its discovery and development leading to emergency use
authorization for treatment of COVID-19. ACS Cent Sci. 6:672–683.
2020.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Gilead announces results from phase 3
trial of investigational antiviral remdesivir in patients with
severe COVID-19. Gilead Sciences, Inc., 2020.
|
|
71
|
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin
Y, Fu S, Gao L, Cheng Z, Lu Q, et al: Remdesivir in adults with
severe COVID-19: A randomised, double-blind, placebo-controlled,
multicentre trial. Lancet. 395:1569–1578. 2020.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Grein J, Ohmagari N, Shin D, Diaz G,
Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, et
al: Compassionate Use of Remdesivir for Patients with Severe
Covid-19. N Engl J Med. 382:2327–2336. 2020.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Adaptive COVID-19 Treatment Trial (ACTT).
uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04280705.
Accessed February 21, 2020.
|
|
74
|
Study to evaluate the safety and antiviral
activity of remdesivir (GS-5734TM) in participants with moderate
coronavirus disease (COVID-19) compared to standard of care
treatment. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04292730.
Accessed March 3, 2020.
|
|
75
|
Study to Evaluate the safety and antiviral
activity of remdesivir (GS-5734TM) in participants with severe
coronavirus disease (COVID-19). uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04292899.
Accessed March 3, 2020.
|
|
76
|
Furuta Y, Komeno T and Nakamura T:
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA
polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci. 93:449–463.
2017.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Furuta Y, Takahashi K, Kuno-Maekawa M,
Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H and Shiraki K:
Mechanism of action of T-705 against influenza virus. Antimicrob
Agents Chemother. 49:981–986. 2005.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Smee DF, Hurst BL, Egawa H, Takahashi K,
Kadota T and Furuta Y: Intracellular metabolism of favipiravir
(T-705) in uninfected and influenza A (H5N1) virus-infected cells.
J Antimicrob Chemother. 64:741–746. 2009.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia
J, Liao X, Gu Y, Cai Q, Yang Y, et al: Experimental treatment with
favipiravir for COVID-19: An open-label control study. Engineering
(Beijing). Mar 18. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print). View Article : Google Scholar
|
|
80
|
Chen C, Huang J, Cheng Z, Wu J, Chen S,
Yongxi Zhang Y, Chen B, Lu M, Luo Y, Zhang J, et al: Favipiravir
versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv.
April 15. 2020.(Epub ahead or ptint). View Article : Google Scholar
|
|
81
|
Clinical study to evaluate the performance
and safety of favipiravir in COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov.
|
|
82
|
Efficacy and safety of favipiravir in
management of COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04349241.
Accessed April 16, 2020.
|
|
83
|
Clinical trial of favipiravir tablets
combine with chloroquine phosphate in the treatment of novel
coronavirus pneumonia. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04319900.
Accessed March 24, 2020.
|
|
84
|
Favipiravir combined with tocilizumab in
the treatment of corona virus disease 2019. uriClinicalTrials.govsimpleClinicalTrials.gov.
|
|
85
|
Cinatl J Jr, Michaelis M, Hoever G,
Preiser W and Doerr HW: Development of antiviral therapy for severe
acute respiratory syndrome. Antiviral Res. 66:81–97.
2005.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Leyssen P, Balzarini J, De Clercq E and
Neyts J: The predominant mechanism by which ribavirin exerts its
antiviral activity in vitro against flaviviruses and
paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J
Virol. 79:1943–1947. 2005.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Ning Q, Brown D, Parodo J, Cattral M,
Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, et al:
Ribavirin inhibits viral-induced macrophage production of TNF,
IL-1, the procoagulant fgl2 prothrombinase and preserves Th1
cytokine production but inhibits Th2 cytokine response. J Immunol.
160:3487–3493. 1998.PubMed/NCBI
|
|
88
|
Sheahan TP, Sims AC, Leist SR, Schäfer A,
Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, et
al: Comparative therapeutic efficacy of remdesivir and combination
lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat
Commun. 11(222)2020.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Agbowuro AA, Huston WM, Gamble AB and
Tyndall JD: Proteases and protease inhibitors in infectious
diseases. Med Res Rev. 38:1295–1331. 2018.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Delang L and Neyts J: Medical treatment
options for COVID-19. Eur Heart J Acute Cardiovasc Care. 9:209–214.
2020.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan
G, Ruan L, Song B, Cai Y, Wei M, et al: A Trial of
Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N
Engl J Med. 382:1787–1799. 2020. View Article : Google Scholar
|
|
92
|
The efficacy of lopinavir plus ritonavir
and arbidol against novel coronavirus infection. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04252885.
Accessed February 5, 2020.
|
|
93
|
Lopinavir/ritonavir ribavirin and IFN-beta
combination for nCoV treatment. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04276688.
Accessed February 19, 2020.
|
|
94
|
Hung IF, Lung KC, Tso EY, Liu R, Chung TW,
Chu MY, Ng YY, Lo J, Chan J, Tam AR, et al: Triple combination of
interferon beta-1b, lopinavir-ritonavir, and ribavirin in the
treatment of patients admitted to hospital with COVID-19: An
open-label, randomised, phase 2 trial. Lancet. 395:1695–1704. 2020.
View Article : Google Scholar
|
|
95
|
Andersen PI, Krpina K, Ianevski A, Shtaida
N, Jo E, Yang J, Koit S, Tenson T, Hukkanen V, Anthonsen MW, et al:
Novel antiviral activities of obatoclax, emetine, niclosamide,
brequinar, and homoharringtonine. Viruses. 11:1–15. 2019.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Choy KT, Wong AY, Kaewpreedee P, Sia SF,
Chen D, Hui KP, Chu DK, Chan MC, Cheung PP, Huang X, et al:
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit
SARS-CoV-2 replication in vitro. Antiviral Res.
178(104786)2020.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Zhang C, Wu Z, Li JW, Zhao HW and Wang GQ:
The cytokine release syndrome (CRS) of severe COVID-19 and
interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the
key to reduce the mortality. Int J Antimicrob Agents. 11:1–6.
2020.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Hennon TR, Penque MD, Abdul-Aziz R,
Alibrahim OS, McGreevy MB, Prout AJ, Schaefer BA, Ambrusko SJ,
Pastore JV, Turkovich SJ, et al: COVID-19 associated multisystem
inflammatory syndrome in children (MIS-C) guidelines; a Western New
York approach. Prog Pediatr Cardiol. 21(101232)2020. View Article : Google Scholar
|
|
99
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu
Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. Lancet.
395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Vijayvargiya P, Garrigos ZE, Almeida NE,
Gurram PR, Stevens RW and Razonable RR: In reply-The ‘Perfect
Cytokine Storm’ of COVID-19. Mayo Clin Proc. May 29. 2020.
View Article : Google Scholar : (Epub ahead of
print). View Article : Google Scholar
|
|
101
|
CORIMUNO-19 - Tocilizumab Trial - TOCI
(CORIMUNO-TOCI). uriClinicalTrials.govsimpleClinicalTrials.gov.
https://www.clinicaltrials.gov/ct2/show/NCT04331808.
Accessed April 2, 2020.
|
|
102
|
Fu B, Xu X and Wei H: Why tocilizumab
could be an effective treatment for severe COVID-19? J Transl Med.
18(164)2020.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Zhang Q, Wang Y, Qi C, Shen L and Li J:
Response to ‘Comments on Zhang et al: Clinical trial analysis of
2019-nCoV therapy registered in China’. J Med Virol.
92(713)2020.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Tocilizumab treatment in patients with
COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04363853.
Accessed April 27, 2020.
|
|
105
|
Tocilizumab in the treatment of
coronavirus induced disease (COVID-19). uriClinicalTrials.govsimpleClinicalTrials.gov.
https://www.clinicaltrials.gov/ct2/show/NCT04335071.
Accessed April 6, 2020.
|
|
106
|
A study to evaluate the safety and
efficacy of tocilizumab in patients with severe COVID-19 pneumonia.
uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04320615.
Accessed March 25, 2020.
|
|
107
|
Genentech's arthritis drug tocilizumab
shows promise in Covid-19 trial. ClinicalTrials Arena, 2020.
https://www.clinicaltrialsarena.com/uncategorized/genentechs-arthritis-drug-tocilizumab-shows-promise-in-covid-19-trial/.
Accessed April 29, 2020.
|
|
108
|
Andreakos E and Tsiodras S: COVID-19:
Lambda interferon against viral load and hyperinflammation. EMBO
Mol Med. 12(e12465)2020.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Davidson S, McCabe TM, Crotta S, Gad HH,
Hessel EM, Beinke S, Hartmann R and Wack A: IFNλ is a potent
anti-influenza therapeutic without the inflammatory side effects of
IFNα treatment. EMBO Mol Med. 8:1099–1112. 2016.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Mehta P, McAuley DF, Brown M, Sanchez E,
Tattersall RS and Manson JJ: HLH Across Speciality Collaboration,
UK. COVID-19: Consider cytokine storm syndromes and
immunosuppression. Lancet. 395:1033–1034. 2020.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Prokunina-Olsson L, Alphonse N, Dickenson
RE, Durbin JE, Glenn JS, Hartmann R, Kotenko SV, Lazear HM, O'Brien
TR, Odendall C, et al: COVID-19 and emerging viral infections: The
case for interferon lambda. J Exp Med. 217:5–8. 2020.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Bray M, Rayner C, Noël F, Jans D and
Wagstaff K: Ivermectin and COVID-19: A report in Antiviral
Research, widespread interest, an FDA warning, two letters to the
editor and the authors' responses. Antiviral Res.
178(104805)2020.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Caly L, Druce JD, Catton MG, Jans DA and
Wagstaff KM: The FDA-approved drug ivermectin inhibits the
replication of SARS-CoV-2 in vitro. Antiviral Res.
178(104787)2020.PubMed/NCBI View Article : Google Scholar
|
|
114
|
González Canga A, Sahagún Prieto AM, Diez
Liébana MJ, Fernández Martínez N, Sierra Vega M and García Vieitez
JJ: The pharmacokinetics and interactions of ivermectin in humans -
a mini-review. AAPS J. 10:42–46. 2008.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Buonfrate D, Salas-Coronas J, Muñoz J,
Maruri BT, Rodari P, Castelli F, Zammarchi L, Bianchi L, Gobbi F,
Cabezas-Fernández T, et al: Multiple-dose versus single-dose
ivermectin for Strongyloides stercoralis infection (Strong Treat 1
to 4): A multicentre, open-label, phase 3, randomised controlled
superiority trial. Lancet Infect Dis. 19:1181–1190. 2019.
View Article : Google Scholar
|
|
116
|
Kelleni MT: Nitazoxanide/azithromycin
combination for COVID-19: A suggested new protocol for early
management. Pharmacol Res. 157(104874)2020.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Padmanabhan S: Potential dual therapeutic
approach against SARS-CoV-2/COVID-19 with nitazoxanide and
hydroxychloroquine. Preprint. 2020.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Ulloa L: The vagus nerve and the nicotinic
anti-inflammatory pathway. Nat Rev Drug Discov. 4:673–684.
2005.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Martineau AR, Jolliffe DA, Hooper RL,
Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa
D, Ginde AA, et al: Vitamin D supplementation to prevent acute
respiratory tract infections: Systematic review and meta-analysis
of individual participant data. BMJ. 356(i6583)2017.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Helming L, Böse J, Ehrchen J, Schiebe S,
Frahm T, Geffers R, Probst-Kepper M, Balling R and Lengeling A:
1α,25-Dihydroxyvitamin D3 is a potent suppressor of interferon
γ-mediated macrophage activation. Blood. 106:4351–4358.
2005.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Ilie PC, Stefanescu S and Smith L: The
role of Vitamin D in the prevention of Coronavirus Disease 2019
infection and mortality. Aging Clin Exp Res. May 6. 2020.PubMed/NCBI View Article : Google Scholar : (Epub ahead of
print). View Article : Google Scholar
|
|
122
|
Alexander OM: Evidence on spironolactone
safety in COVID-19 reassuring. Medscape. April 29. 2020.(Epub ahead
of print).
|
|
123
|
Gustavo Carlos Wambier GA: Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely
to be androgen mediated. J Am Acad Dermatol. 21:1–9.
2020.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Jin JM, Bai P, He W, Wu F, Liu XF, Han DM,
Liu S and Yang JK: Gender differences in patients with COVID-19:
Focus on severity and mortality. Front Public Health.
8(152)2020.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Spironolactone in Covid-19 Induced ARDS.
uriClinicalTrials.govsimpleClinicalTrials.gov.
https://www.smartpatients.com/trials/NCT04345887.
Accessed April, 2020.
|
|
126
|
Kleinnijenhuis J, Quintin J, Preijers F,
Benn CS, Joosten LA, Jacobs C, van Loenhout J, Xavier RJ, Aaby P,
van der Meer JW, et al: Long-lasting effects of BCG vaccination on
both heterologous Th1/Th17 responses and innate trained immunity. J
Innate Immun. 6:152–158. 2014.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Gearoid R: Japan was expecting a
coronavirus explosion. Where is it? The Japan Times. 2020.
|
|
128
|
Moorlag SJ, Arts RJ, van Crevel R and
Netea MG: Non-specific effects of BCG vaccine on viral infections.
Clin Microbiol Infect. 25:1473–1478. 2019.PubMed/NCBI View Article : Google Scholar
|
|
129
|
BCG Vaccination to Protect Healthcare
Workers Against COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04327206.
Accessed March 31, 2020.
|
|
130
|
BCG vaccine for health care workers as
defense against COVID-19. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04348370.
Accessed April 16, 2020.
|
|
131
|
Saad M and Elsalamony R: Measles vaccines
may provide partial protection against COVID-19. Int J Cancer
Biomed Res. 5:14–19. 2020. View Article : Google Scholar
|
|
132
|
Fischer JC, Zänker K, van Griensven M,
Schneider M, Kindgen-Milles D, Knoefel WT, Lichtenberg A,
Tamaskovics B, Djiepmo-Njanang FJ, Budach W, et al: The role of
passive immunization in the age of SARS-CoV-2: An update. Eur J Med
Res. 25(16)2020.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Keith P, Day M, Perkins L, Moyer L, Hewitt
K and Wells A: A novel treatment approach to the novel coronavirus:
An argument for the use of therapeutic plasma exchange for
fulminant COVID-19. Crit Care. 24(128)2020. View Article : Google Scholar
|
|
134
|
Lennart H, Hassan A, Fausto B, Harold M
and Hammarström QP: Development of passive immunity against
SARS-CoV-1 2 for management of immunodeficient patients - a
perspective. J Allergy Clin Immunol. May 12. 2020.(Epub ahead of
print). View Article : Google Scholar
|
|
135
|
Honore PM, Mugisha A, Kugener L, Redant S,
Attou R, Gallerani A and De Bels D: Therapeutic plasma exchange as
a routine therapy in septic shock and as an experimental treatment
for COVID-19: We are not sure. Crit Care. 24(226)2020.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Treatments for COVID-19: Canadian Arm of
the SOLIDARITY Trial. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT04330690.
Accessed April 1, 2020.
|
|
137
|
Randomized embedded multifactorial
adaptive platform trial for community- acquired pneumonia.
uriClinicalTrials.govsimpleClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT02735707.
Accessed April 13, 2016.
|
|
138
|
Trial of treatments for COVID-19 in
hospitalized adults. uriClinicalTrials.govsimpleClinicalTrials.gov.
https://www.centerwatch.com/clinical-trials/listings/241173/corona-virus-infection-trial-treatments-covid-19-hospitalized/?&radius=50.
Accessed June 2020.
|
